AstraZeneca

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AstraZeneca and other ETFs, options, and stocks.

About AZN

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. 

CEO
Pascal Soriot
CEOPascal Soriot
Employees
96,100
Employees96,100
Headquarters
Cambridge, Cambridgeshire
HeadquartersCambridge, Cambridgeshire
Founded
1913
Founded1913
Employees
96,100
Employees96,100

AZN Key Statistics

Market cap
257.93B
Market cap257.93B
Price-Earnings ratio
24.72
Price-Earnings ratio24.72
Dividend yield
1.68%
Dividend yield1.68%
Average volume
2.83M
Average volume2.83M
High today
$167.52
High today$167.52
Low today
$165.10
Low today$165.10
Open price
$165.69
Open price$165.69
Volume
1.57M
Volume1.57M
52 Week high
$212.71
52 Week high$212.71
52 Week low
$147.37
52 Week low$147.37

Stock Snapshot

With a market cap of 257.93B, AstraZeneca(AZN) trades at $166.28. The stock has a price-to-earnings ratio of 24.72 and currently yields dividends of 1.68%.

On 2026-09-29, AstraZeneca(AZN) stock moved within a range of $165.10 to $167.52. With shares now at $166.28, the stock is trading +0.7% above its intraday low and -0.7% below the session's peak.

Trading activity shows a volume of 1.57M, compared to an average daily volume of 2.83M.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $147.37.

Over the past 52 weeks, AstraZeneca(AZN) stock has traded between a high of $212.71 and a low of $147.37.

AZN News

Investing.com 5h
AstraZeneca seeks U.S. FDA approval for lung cancer treatment - Investing.com

...

AstraZeneca seeks U.S. FDA approval for lung cancer treatment - Investing.com
TipRanks 7h
Closing Bell Movers: Summit Therapeutics jumps on AstraZeneca investment

Major indices started the week on a downswing as oil prices sprang higher after President Donald Trump rejected conditions for a ceasefire presented by Iran and...

The Wall Street Journal 8h
AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

AstraZeneca is investing $2 billion into Summit Therapeutics as part of an expanded partnership. Avishek Das / Zuma Press AstraZeneca AZN -0.48 %decrease; down...

AstraZeneca to Invest $2 Billion in Summit Therapeutics, Collaborate on Cancer Drugs

Analyst ratings

100%

of 10 ratings
Buy
100%
Hold
0%
Sell
0%

More AZN News

Seeking Alpha 9h
Summit Therapeutics rises after AstraZeneca commits $2B investment

Summit (SMMT) and AstraZeneca (ANZ) announced on Monday that the companies have entered into an agreement whereby AstraZeneca will make an equity investment of...

Summit Therapeutics rises after AstraZeneca commits $2B investment
Bloomberg 9h
Summit Therapeutics Jumps on $2 Billion AstraZeneca Deal - Bloomberg

...

Summit Therapeutics Jumps on $2 Billion AstraZeneca Deal - Bloomberg
TipRanks 9h
Summit Therapeutics, AstraZeneca enter clinical collaboration agreement

Summit (SMMT) entered into a clinical collaboration agreement with AstraZeneca (AZN) to evaluate sonesitatug vedotin in combination with ivonescimab with the in...

TipRanks 9h
AstraZeneca makes $2B equity investment in Summit Therapeutics

Summit Therapeutics (SMMT) announced key developments important to the company’s progress towards achieving its goal of making a significant difference in the l...

TipRanks 14h
AstraZeneca Advances Fixed-Dose Cholesterol Combo With Completed Phase I Bioavailability Study

AstraZeneca plc (GB:AZN) announced an update on their ongoing clinical study. AstraZeneca (AZN) has completed a Phase I study titled “A Phase I, Randomized, Op...

TipRanks 4d
AstraZeneca Updates Real‑World Kidney Cancer Study in China, Offering Fresh Clues for Oncology Investors

AstraZeneca ($~AZN) announced an update on their ongoing clinical study. The study Real World Study of Effectiveness of Sunitinib or Sorafenib looks at how two...

TipRanks 4d
AstraZeneca’s sBLA for IMFINZI plus enfortumab vedotin granted Priority Review

AstraZeneca’s (AZN) supplemental Biologics License Application for IMFINZI in combination with enfortumab vedotin has been accepted and granted Priority Review...

People also own

Based on the portfolios of people who own AZN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.